Efficacy of autologous platelet‐rich plasma combined with a non‐cross‐linked hyaluronic acid compound in the treatment of female androgenetic alopecia: A retrospective, case‐series study

Abstract

AbstractBackgroundFemale androgenetic alopecia (FAGA) is a condition that affects women and involves the gradual loss of terminal hair in specific areas of the scalp. The limited treatment options for FAGA necessitate the development of new strategies. This study aimed to evaluate the potential benefit of using a combination therapy composed of autologous platelet‐rich plasma (PRP) and a non‐cross‐linked hyaluronic acid (HA) compound in the treatment of FAGA.MethodsThis was a retrospective, case‐series study, which enrolled nine female patients with FAGA between September 2021 and December 2022. The non‐cross‐linked HA compound (Hearty®, Imeik Technology Development Co., Ltd.) and PRP were implanted into the areas of hair loss over four treatment sessions separated by 4‐week intervals. Patients were monitored for overall improvement in their hair loss, hair count, treatment satisfaction, and adverse events at 1, 3, and 6 months follow‐up.ResultsThe improvement rates, subjectively evaluated by the study physician, were 88.89% at the 1‐month and 100% at the 3‐month follow‐up, relative to baseline. Moreover, the quantitative evaluation results showed that the FAGA patients' hair density increased by 54.51% at the 1‐month and by 77.25% at the 3‐month follow‐up.ConclusionThe combination of PRP and non‐cross‐linked HA compound appeared to be a certain positive effective procedure for FAGA without serious adverse event. We envisage that this work will contribute to the development of new treatment options for women suffering from this condition.